NCT06005441View on ClinicalTrials.gov

A Phase 2b Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat.

PHASE2CompletedINTERVENTIONAL
Enrollment

173

Participants

Timeline

Start Date

November 10, 2023

Primary Completion Date

October 18, 2024

Study Completion Date

October 18, 2024

Conditions
Subcutaneous Fat
Interventions
DRUG

CBL-514 injection

Provided as a ready for use injectable CBL-514 solution

DRUG

CBL-A1 Injection

Provided as a ready for use injectable CBL-A1 solution

DRUG

CBL-A2 Injection

Provided as a ready for use injectable CBL-A2 solution

DRUG

0.9% Sodium Chloride

Sodium Chloride (0.9% NaCl) placebo for injection

Trial Locations (1)

68144

Investigational Site 1, Omaha

Sponsors
All Listed Sponsors
lead

Caliway Biopharmaceuticals Co., Ltd.

INDUSTRY

NCT06005441 - A Phase 2b Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat. | Biotech Hunter | Biotech Hunter